Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Claret Bioscience LLC has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners across 3 distinct art units. This structure indicates that each pending action is being handled by a different examiner in a different group. The 3 distinct art units suggest a variety of biotechnological subjects are currently under review. This distribution shows that the company is pursuing multiple technical paths that require engagement with various specialized groups at the office. The administrative path is defined by these 3 separate units, which affects prosecution timelines.
BAILEY CHEYENNE BUCHANAN is the busiest examiner for the portfolio, holding 1 pending office action. Given the 3 pending office actions and 3 distinct examiners, the workload is distributed equally. For a practitioner, this means the prosecution strategy must account for the distinct preferences of 3 different examiners across 3 separate administrative units. The lack of concentration in a single art unit requires navigating different procedural nuances within the office. Managing 3 pending office actions across 3 distinct examiners requires a broad approach to examiner engagement and a thorough understanding of each examiner's specific history.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
| STRIEGEL, THEODORE CHARLES | 1 | 21.9% | +23.6% |
| SMITH, EMILIE ALINE | 1 | 49.4% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17766031 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SMITH, EMILIE ALINE | 87d overdue |
| 18280588 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | BUCHANAN, BAILEY CHEYENNE | — |
| 18029550 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | STRIEGEL, THEODORE CHARLES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17766031 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SMITH, EMILIE ALINE | 87d overdue |
| 18280588 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | BUCHANAN, BAILEY CHEYENNE | — |
| 18029550 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | STRIEGEL, THEODORE CHARLES | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1685 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280588 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | BUCHANAN, BAILEY CHEYENNE | 1682 | §103§112 | Final Rejection | — | Pending | Sep 06, 2023 |
| 18029550 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | STRIEGEL, THEODORE CHARLES | 1685 | §101§103 | Non-Final OA | — | Pending | Mar 30, 2023 |
| 17766031 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SMITH, EMILIE ALINE | 1686 | §101§103 | Non-Final OA | 87d overdue | Pending | Apr 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialClaret Bioscience LLC has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Bailey Cheyenne Buchanan has the most, with 1 of Claret Bioscience LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
